The purpose of the prospective, open, randomized controlled, multicenter, exploratory clinical study is to evaluate efficacy and safety of NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus NALIRIFOX for Conversion Therapy for Locally Advanced Pancreatic Cancer
Histologically or cytologically confi rmed pancreatic cancer;
ECOG performance no more than 1;
Radiographically assessed as locally advanced pancreatic cancer according ;
No previous anti-tumor therapy;
Prior anti-tumor therapy of any kind;
Known to be symptomatic central nervous system metastasis and/or cancerous meningitis.
Patients with autoimmune disease or immune deficiency who are treated with immuno-suppressive drugs;
Patients with bleeding tendency;